ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
Open Access
- 9 February 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (10) , 17164-17190
Abstract
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancerKeywords
This publication has 73 references indexed in Scilit:
- Epigenetic and genetic features of 24 colon cancer cell linesOncogenesis, 2013
- Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancerOncology Letters, 2013
- Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patientsBritish Journal of Cancer, 2011
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- The Regulation of Class IA PI 3-Kinases by Inter-Subunit Interactions2010
- A frequent kinase domain mutation that changes the interaction between PI3Kα and the membraneProceedings of the National Academy of Sciences, 2009
- The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shoresNature Genetics, 2009
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patientsAnnals of Oncology, 2008
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001